Ken Griffin 2seventy Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.85 - $5.05 $112,805 - $147,965	29,300 Added 263.96%	40,400 $190,000
Q2 2024 Aug 14, 2024	SELL	$3.6 - $5.79 $105,480 - $169,647	-29,300 Reduced 72.52%	11,100 $42,000
Q1 2024 May 15, 2024	BUY	$3.09 - $6.0 $110,893 - $215,328	35,888 Added 795.39%	40,400 $216,000
Q4 2023 Feb 14, 2024	SELL	$1.57 - $4.58 $4,293 - $12,526	-2,735 Reduced 37.74%	4,512 $19,000
Q3 2023 Nov 14, 2023	SELL	$3.14 - $11.2 $42,390 - $151,200	-13,500 Reduced 65.07%	7,247 $28,000
Q2 2023 Aug 14, 2023	SELL	$8.45 - $12.48 $20,280 - $29,952	-2,400 Reduced 10.37%	20,747 $209,000
Q1 2023 May 15, 2023	SELL	$9.21 - $14.98 $242,508 - $394,438	-26,331 Reduced 53.22%	23,147 $236,000
Q4 2022 Feb 14, 2023	BUY	$8.57 - $17.0 $31,229 - $61,948	3,644 Added 7.95%	49,478 $463,000
Q3 2022 Nov 14, 2022	BUY	$12.56 - $17.54 $217,149 - $303,249	17,289 Added 60.57%	45,834 $667,000

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $116M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.